Skip to main content
Applied Microbiology logoLink to Applied Microbiology
. 1969 Jun;17(6):861–865. doi: 10.1128/am.17.6.861-865.1969

Antimycobacterial Activity of Rifampin Under In Vitro and Simulated In Vivo Conditions

K D Stottmeier 1, G P Kubica 1, C L Woodley 1
PMCID: PMC377827  PMID: 4978926

Abstract

Minimal inhibitory concentrations of rifampin for different species of mycobacteria were determined in 7H-10 agar medium and Lowenstein-Jensen egg medium. When rifampin was incorporated into egg medium, approximately 90% of its activity was lost. The stability of rifampin was tested during storage at different temperatures and concentrations. When tested in agar medium, a combination of isoniazid (INH) and rifampin inhibited multiple drug-resistant strains of Mycobacterium intracellulare, but under simulated in vivo conditions the drugs did not eliminate these same organisms. Drug-resistant mutants of M. intracellulare multiplied during an 8-day period when exposed 10 hr daily to the INH-rifampin regimen. However, combinations of rifampin and INH reduced drug-resistant mycobacterial populations by 99%, an effect which could not be enhanced by the addition of either erythromycin, ethionamide, or cycloserine.

Full text

PDF
863

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CANETTI G., RIST N., GROSSET J. [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris) 1963 Feb-Mar;27:217–272. [PubMed] [Google Scholar]
  2. Clark J., Wallace A. The susceptibility of mycobacteria to rifamide and rifampicin. Tubercle. 1967 Jun;48(2):144–148. doi: 10.1016/s0041-3879(67)80009-6. [DOI] [PubMed] [Google Scholar]
  3. Gyselen A., Verbist L., Cosemans J., Lacquet L. M., Vandenbergh E. Rifampin and ethambutol in the retreatment of advanced pulmonary tuberculosis. Am Rev Respir Dis. 1968 Dec;98(6):933–941. doi: 10.1164/arrd.1968.98.6.933. [DOI] [PubMed] [Google Scholar]
  4. Hobby G. L., Lenert T. F. The antimycobacterial activity of rifampin. Am Rev Respir Dis. 1968 Apr;97(4):713–714. doi: 10.1164/arrd.1968.97.4.713. [DOI] [PubMed] [Google Scholar]
  5. Pines A., Raafat H., Bundi R. The rifamycins with other drugs in the treatment of pulmonary tuberculosis: a report of nine cases. Tubercle. 1967 Dec;48(4):281–287. doi: 10.1016/s0041-3879(67)80035-7. [DOI] [PubMed] [Google Scholar]
  6. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]
  7. Wayne L. G., Krasnow I. Preparation of tuberculosis susceptibility testing mediums by means of impregnated disks. Am J Clin Pathol. 1966 Jun;45(6):769–771. doi: 10.1093/ajcp/45.6_ts.769. [DOI] [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES